<DOC>
	<DOCNO>NCT02205606</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety HCP1306 patient primary hypercholesterolemia .</brief_summary>
	<brief_title>Efficacy/Safety HCP1306 Tablet Versus HGP0816 Tablet Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Aged 19 year Signed informed consent At visit 1 , LDLC ≤ 250mg/dL Triglyceride &lt; 400 mg/dL After 4 week TLC , At visit2 , LDLC ≤ 250mg/dL , Triglyceride &lt; 400 mg/dL satisfy criterion accord Risk cardiovascular disease Current past history hypersensitivity HMGCoA reductase inhibitor component Ezetimibe Has active liver disease severe liver disorder ( continous elevation AST , ALT level exceed 3 time normal upper limit ) Has severe renal failure kidney injury ( Creatinine level exceed 2 time normal upper limit ) CK level exceed 5 time normal upper limit Uncontrolled hypertension patient ( SBP≥ 180 mmHg DBP ≥ 110 mmHg ) Uncontrolled diabetes mellitus patient ( HbA1c ≥ 9 % ) Uncontrolled malfunctional thyroidism ( previsit 2 , TSH level exceed 1.5 time normal upper limit )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>